{"id":137093,"date":"2026-07-01T17:00:09","date_gmt":"2026-07-01T11:30:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=137093"},"modified":"2026-10-08T09:46:44","modified_gmt":"2026-10-08T04:16:44","slug":"sun-pharma-advanced-research-company-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-advanced-research-company-share-price-target-2026\/","title":{"rendered":"Sun Pharma Advanced Research Company Share Price Target 2026: Stock Analysis, Share Price Today, Bull Case and Bear Case After Q1 FY27"},"content":{"rendered":"
\n

META TITLE:<\/strong> Sun Pharma Advanced Research Company Share Price Target 2026<\/p>\n

META DESCRIPTION:<\/strong> Sun Pharma Advanced Research Company share price target 2026: Rs 164 to Rs 213 vs Rs 196.79. Share price today, stock analysis, buy or sell, bull and bear case.<\/p>\n

SLUG:<\/strong> sun-pharma-advanced-research-company-share-price-target-2026<\/p>\n

PRIMARY KEYWORD:<\/strong> Sun Pharma Advanced Research Company share price target<\/p>\n

SECONDARY KEYWORDS:<\/strong> Sun Pharma Advanced Research Company share price today, Sun Pharma Advanced Research Company stock analysis, Sun Pharma Advanced Research Company buy or sell, Sun Pharma Advanced Research Company share price forecast, Sun Pharma Advanced Research Company stock price target 2027, Sun Pharma Advanced Research Company price target, Sun Pharma Advanced Research Company buy or sell<\/p>\n

LSI KEYWORDS:<\/strong> analyst consensus, bull case, bear case, 12-month target, PE multiple, EPS estimate, sector tailwinds, institutional holding, resistance level, FY27 outlook<\/p>\n<\/div>\n

Sun Pharma Advanced Research Company Rs 196.79 (7 Oct 2026 close). 52-week range Rs 108.00 to Rs 289.00. Q1 FY27 consolidated loss Rs 20.78 cr; trailing EPS Rs 48.82 from a one-time voucher sale.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The Sun Pharma Advanced Research Company share price target for 2026 is Rs 164 to Rs 213, which is between 17 percent below and 8 percent above the last close of Rs 196.79, with bull and bear cases of Rs 238 to Rs 287 and Rs 102 to Rs 144. Sun Pharma Advanced Research Company reported a Q1 FY27 consolidated net loss of Rs 20.78 crore against Rs 51.87 crore a year ago, after a one-time Rs 29.21 crore licence termination payment lifted revenue to Rs 39.92 crore. The trailing P\/E of about 4 times comes from a one-time priority review voucher sale in Q4 FY26 that produced a Rs 1,761 crore profit, so it cannot be repeated, and the stock trades at 4.8 times book value. No brokerage price target was available on the sources we track as of 7 October 2026, so every range below is a Univest research scenario.<\/p>\n<\/p><\/div>\n

The Sun Pharma Advanced Research Company<\/a> share price target for 2026 is Rs 164 to Rs 213 in the Univest base case, with the stock at Rs 196.79 at the 7 October 2026 close. That is 31.9 percent below its 52-week high of Rs 289.00 and 82.2 percent above its 52-week low of Rs 108.00, and the stock moved up 46.8 percent over the past year. Sun Pharma Advanced Research Company, or SPARC, is a clinical-stage pharma R&D company in the Sun Pharma group. Debt to equity is 0.42 and the company pays no dividend.<\/p>\n

Three things changed since the last update: Q1 FY27 results on 10 August showed a narrower loss helped by a one-time licence payment, the board approved promoter reclassifications, and the stock fell about 32 percent from its Rs 289 July spike. This Sun Pharma Advanced Research Company stock analysis covers the Sun Pharma Advanced Research Company share price today, the Sun Pharma Advanced Research Company share price target for 2026, 2027 and 2030, the Q1 FY27 numbers, catalysts and risks, key price levels and a Sun Pharma Advanced Research Company buy or sell view.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n